Co‐expression of urokinase, urokinase receptor and PAI‐1 is necessary for optimum invasiveness of cultured lung cancer cells

International Journal of Cancer

Volumn 60, Issue 4, 1995, Pages 501-506

  Liu, Guohui ^a   Shuman, Marc A ^a   Cohen, Robert L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; MATRIGEL; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CELL INVASION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG CARCINOMA; PRIORITY JOURNAL; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; HUMAN; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, CELL SURFACE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0028900705     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.2910600413     Document Type: Article

References (23)

1. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue
2. Plasminogen activator inhibitor type 1 stabilizes vitronectin‐dependent adhesions in HT‐1080 cells
3. Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells
4. Prevention of metastasis by inhibition of the urokinase receptor
5. Prognostic value of urokinase‐type plasminogen activator in 671 primary breast cancer patients
6. High levels of urokinase‐type plasminogen activator and its inhibitor PAI‐I in cytosolic extracts of breast carcinomas are associated with poor prognosis
7. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase
8. Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors
9. Solubilization and degradation of subendolhelial matrix glycoproteins and proteoglycans by metastatic tumor cells
10. Effect of plasminogen activator (urokinase), plasmin. and thrombin on glycoprotein and collagenous components of basement membrane
11. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene
12. Transforming growth factor‐beta 1 modulates basic fibroblast growth factor‐induced proteolytic and angiogenic properties of endothelial cells in vitro
13. Proteolytic balance and capillary. morphogenesis
14. Urokinase‐type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas
15. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase‐type plasminogen activator, its type‐1 inhibitor, and uroki‐nase‐mediated matrix degradation
16. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis
17. Immunocytochemical localization of urokinase‐type plasminogen activator in Lewis lung carcinoma
18. M15 cluster report: CD87
19. Bimodal relationship between invasion of the amniotic membrane and plasminogen activator activity
20. Identification and primary sequence of an unspliced human urokinase poly(A) RNA
21. Cytokines induce urokinase‐dependent adhesion of human myeloid cells
22. Endogenous activation of latent collagenase by rheumatoid synovial cells: evidence for a role of plasminogen activator
23. cDNA cloning and expression in E. coli of a plasminogen activator inhibitor (PAI) related to a PAI produced by HepG2 hepatoma cells